← All trials
NCT04689035
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 27, 2020
- Primary completion
- Feb 20, 2021
- Completion date
- Apr 2, 2021
- First posted
- Dec 30, 2020
- Last posted
- Dec 30, 2020
- Enrollment
- 48
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Avilex PharmaLead sponsor
- Clinical Research Services TurkuOverall official - principal investigator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.